Deutsch Website, wo Sie Qualität und günstige https://medikamenterezeptfrei2014.com/ Viagra Lieferung weltweit erwerben.

Ein wenig Kopfschmerzen, aber schnell verging der Schmerz. Gefühle, die ich erlebte ein unvergessliches cialis kaufen Ehrlich gesagt nicht wirklich glauben, in der Kraft Viagra. Setzte nach der Anleitung. Das Ergebnis ist natürlich, sich selbst rechtfertigte.

Microsoft word - nv_mm_bogar_20100511_en.doc


Press Release
Zurich, 11 May 2010

Information on New Value’s portfolio company Bogar AG

Bogar’s Board extended with industry expert – New Value participates
in capital increase

Bogar AG, a portfolio company of New Value, (SIX: NEWN), nominates to elect Peter Haensli as
new Board member on the occasion of an upcoming shareholders meeting. Mr Haensli is a
longtime pet industry expert. Moreover, Bogar successfully closed a financing round of CHF 1.3
million. New Value participated with CHF 0.75 million and is now holding a 31.6%-stake in Bogar’s
share capital. Bogar introduces its new products at the Interzoo 2010, the world’s leading pet
industry exhibition. Among the new products are biocidals and herbal food supplies, especially a
one-of-a-kind anti-accarid gel for pets.
Bogar, a specialist for future-oriented animal health and food products based on herbal ingredients, plans
to strengthen the Board and prepares for the next growth phase. At the upcoming extraordinary
shareholders meeting in June 2010, the management proposes to elect Peter Haensli as Board member. It is
intended by the company, that he will be appointed chairman of the board. Peter Haensli is a longtime pet
industry expert and former Board member of Vitakraft, responsible for sales and logistics. He was also
CEO of Vitakraft International AG Switzerland. Vitakraft ist a major brand name in the pet industry with
2,400 staff members and a turnover of EUR 300 million in Europe, USA and Asia. Bogar’s management
will be actively supported by Peter Haensli and will benefit from his longterm experience in marketing and
sales. „Bogar is a fascinating growth story with great potential. I hope to be able to bring in my longterm
experience in the most profitable ways and am looking forward to this new challenge with the dedicated
and competent Bogar team,“ Mr Haensli comments.
At the end of April, Bogar successfully closed a financing round of CHF 1.3 million, where New Value
participated with CHF 0.75 Million in both share capital and convertible loans. The remaining financing is
provided by other existing as well as new investors. CEO Marius Fuchs comments „We will use the new
funds to extend our product range and further develop the European sales network.
At «Interzoo 2010», Bogar will introduce new products. This is the world’s leading pet industry exhibition
taking place midmonth in Nuremberg, Germany. In particular, Bogar presents the new „bogadual®“, a
gentle anti-flea agent for cats and dogs as well as a new anti-accarid gel. These innovative products are
based on the herbal component Margosa. The product lines of food additives will be extended with
„bogafit® Anti-Aging“, based on ginseng and „bogafit® Verdauung“, based on artichoke for digestion
disorders. Including these novelties, the Bogar range now involves more than 20 products for pets and
horses.
Information about Bogar AG
Bogar specializes in natural and future-oriented animal health and nutrition and develops, produces and
markets quality plant-based food supplements and care products. Bogar is a leader in the area of veterinary
phytotherapy and the developer of an ever-growing product catalog for effective supportive nutrition and
the natural prevention and treatment of various somatic disorders and diseases in animals. The current
product range consists of effective nutritional supplements as well as high-quality care preparations for
dogs, cats and horses. Please find further information at www.bogar.com

Information about New Value AG
New Value, listed at the SIX Swiss Exchange, invests directly in promising private companies in Switzerland
and neighbouring countries with above-average market and growth potential. As an investment company,
New Value promotes innovative business models with venture capital and accompanies those to market
success. The portfolio covers companies of different stages of development, starting with the market
introduction phase up to medium-sized enterprises with stable profits. A broad investment approach is
deliberately followed regarding industry sectors. The portfolio contains companies active in Cleantech and
Healthcare. New Value assigns great value to ethical business concepts and good corporate governance while
selecting their portfolio companies. Criteria such as meaningfulness, social responsibility and ecological
sustainability are considered by New Value as decisive competitive advantages, which affect and enhance the
quality of products and services offered and thus, facilitate an above average increase of value potential. Since
the formation of New Value, EPS Value Plus AG, Zurich, has served as investment manager.
Börsennotierung
SIX Swiss Exchange (www.six-swiss-exchange.com) Xetra, Open Market Frankfurt, Berlin, Düsseldorf, Stuttgart und München Ticker-Symbole
Valorennummer
WP-Kennnummer

Informationen/
Downloads
New Value AG | Bodmerstrasse 9 | CH - 8027 Zürich | Tel. +41 (0)43 344 38 38 | www.newvalue.ch

Source: http://www.newvalue.ch/fileadmin/userupload/dokumente/NV_MM_Bogar_20100511_EN.pdf

Microsoft word - 2010 bk - cv jad final 9 20 10.doc

CURRICULUM VITAE Joseph Anthony DiPietro The University of TennesseeInstitute of Agriculture2621 Morgan Circle DriveRoom 101 Morgan HallKnoxville, Tennessee 37996-4505(865) 974-7342 (Office phone)Email) DATE OF BIRTH : PLACE OF BIRTH : MARITAL STATUS : Married Deborah Sue Brown -8/3/74Three Children: Robin Rebecca -3/10/77Joseph Alphonso -5/11/81Rose Elizabeth -2/23/83 EDUCATION:

Gebrauchsinformation: information für den anwender

Gebrauchsinformation: Information für den Anwender Myambutol® 400 mg, Filmtabletten Wirkstoff: Ethambutoldihydrochlorid Zur Anwendung bei Kindern ab 6 Jahren und Erwachsenen Lesen Sie die gesamte Packungsbeilage sorgfältig durch, bevor Sie mit der Einnahme dieses Arzneimittels beginnen.  Heben Sie die Packungsbeilage auf. Vielleicht möchten Sie diese später nochmals lesen

Copyright © 2010-2014 Health Drug Pdf